Sufentanil Hameln
Potent synthetic opioid analgesic for anesthesia and perioperative pain management
Sufentanil Hameln is a highly potent synthetic opioid analgesic used exclusively in hospital settings for anesthesia and perioperative pain management. Approximately 5–10 times more potent than fentanyl and 500–1,000 times stronger than morphine, sufentanil is administered intravenously during major surgeries or epidurally for postoperative and obstetric pain relief. It must only be given under the direct supervision of a qualified anesthesiologist with immediate access to resuscitation equipment.
Quick Facts
Key Takeaways
- Sufentanil Hameln is one of the most potent opioids in clinical use, reserved exclusively for hospital-based anesthesia and controlled pain management settings.
- It is administered either intravenously for surgical anesthesia or epidurally for postoperative pain relief, labor analgesia, and post-cesarean pain management.
- Respiratory depression is the most serious risk and may persist into the recovery period or recur during awakening — continuous monitoring is essential.
- Concurrent use with benzodiazepines, other CNS depressants, or serotonergic drugs significantly increases the risk of life-threatening complications.
- MAO inhibitors must be discontinued at least 2 weeks before any surgical procedure involving sufentanil.
What Is Sufentanil Hameln and What Is It Used For?
Quick Answer: Sufentanil Hameln is a potent synthetic opioid analgesic belonging to the phenylpiperidine class. It is used exclusively in hospitals for induction and maintenance of general anesthesia during major surgery, and for epidural pain relief after surgery, during labor, and following cesarean delivery.
Sufentanil belongs to the pharmacological group of opioid analgesics — medications that act on opioid receptors in the central nervous system to prevent and relieve pain. It was first synthesized in the 1970s as part of the ongoing development of synthetic opioids following the introduction of fentanyl, and received regulatory approval for clinical use in the 1980s. Sufentanil is structurally related to fentanyl but features a thienyl group substitution that confers significantly greater potency and a more favorable pharmacokinetic profile in certain clinical scenarios.
The drug acts primarily as an agonist at mu-opioid receptors, producing profound analgesia, sedation, and dose-dependent respiratory depression. In terms of potency, sufentanil is approximately 5 to 10 times more potent than fentanyl and 500 to 1,000 times more potent than morphine on a weight-for-weight basis. This exceptional potency means that only very small doses are required to achieve the desired analgesic and anesthetic effects, which can be advantageous in terms of cardiovascular stability during major surgical procedures.
Sufentanil Hameln is specifically formulated as a sterile, clear, and colorless solution available in two concentrations: 5 micrograms per milliliter and 50 micrograms per milliliter. The lower concentration is typically used for epidural administration, while the higher concentration is more commonly employed for intravenous use during major operations.
Intravenous Uses in Adults
When given intravenously, Sufentanil Hameln is used to provide analgesia during induction and maintenance of anesthesia in combination with other anesthetic agents such as propofol, thiopental, or volatile anesthetic gases. For major surgical procedures that require mechanical ventilation — including cardiac surgery, major abdominal operations, and neurosurgery — sufentanil can serve as the primary analgesic component of a balanced anesthetic technique. The drug’s rapid onset of action (typically within 1–3 minutes after intravenous injection) and relatively short duration of effect make it well suited for careful titration during surgical procedures of varying length.
Epidural Uses in Adults
Epidural administration of Sufentanil Hameln involves injection into the epidural space surrounding the spinal cord. This route is used for postoperative pain management following major surgical procedures, pain relief after cesarean section, and analgesia during labor and vaginal delivery. When given epidurally, sufentanil provides potent pain relief while allowing the patient to remain conscious and cooperative, which is particularly valuable during childbirth. Epidural sufentanil is often combined with local anesthetics such as bupivacaine to provide synergistic analgesia with reduced side effects from either agent alone.
Use in Children
Intravenous sufentanil may be used in children older than one month for analgesia during induction and maintenance of combined anesthesia. The dosage is carefully calculated based on body weight, the type and duration of the surgical procedure, and the concurrent use of other anesthetic agents. Epidural sufentanil is approved for children aged one year and older for the management of postoperative pain following general surgery, thoracic surgery, and orthopedic procedures. Children must be monitored for signs of respiratory depression for at least 2 hours after epidural administration.
Sufentanil Hameln is administered only by specialist physicians (anesthesiologists) in hospital settings or other facilities equipped with artificial ventilation equipment and postoperative monitoring capabilities. It is never given for self-administration at home.
What Should You Know Before Taking Sufentanil Hameln?
Quick Answer: Sufentanil Hameln must not be used in patients with respiratory disease, those taking MAO inhibitors, or patients with acute intermittent porphyria. Special caution is needed in patients with lung, liver, kidney, or thyroid disease, reduced blood volume, or raised intracranial pressure.
Before receiving Sufentanil Hameln, your anesthesiologist will conduct a thorough preoperative assessment to determine whether this medication is appropriate for you. This assessment includes reviewing your complete medical history, current medications, allergies, and any previous experiences with anesthesia. Understanding the contraindications and precautions associated with sufentanil is essential for safe use, as this is an extremely potent medication with a narrow therapeutic window.
Contraindications — Intravenous Use
You must not receive intravenous Sufentanil Hameln if you have any of the following conditions or circumstances:
- Allergy to sufentanil, other opioid analgesics, or any of the excipients in the formulation (sodium chloride, citric acid monohydrate, water for injections).
- Respiratory disease causing breathing difficulties, such as asthma or chronic obstructive pulmonary disease (COPD).
- Current or recent MAO inhibitor therapy — these antidepressant medications must be discontinued at least 2 weeks before surgery.
- Acute intermittent porphyria, a rare inherited liver enzyme disorder.
- Current or recent use of partial opioid agonists/antagonists such as nalbuphine, buprenorphine, or pentazocine, which can precipitate acute withdrawal in opioid-dependent patients.
- During labor or before the umbilical cord has been clamped during cesarean section (intravenous route only).
Contraindications — Epidural Use
Epidural administration of Sufentanil Hameln is contraindicated in the following additional situations:
- Severe hemorrhage or hypovolemic shock
- Severe systemic infection or septicemia
- Infection at the proposed injection site
- Impaired wound healing at the injection site
- Significant coagulation disorders or concurrent anticoagulant therapy that would increase the risk of epidural hematoma
Warnings and Precautions
Inform your anesthesiologist before receiving Sufentanil Hameln if you have any of the following conditions, as they may require dose adjustment, additional monitoring, or special precautions:
- Abnormally slow intestinal motility or constipation
- Disease of the gallbladder or pancreas
- Personal or family history of substance abuse (alcohol, prescription medications, or illicit drugs)
- History of smoking or tobacco use
- Mental health conditions including depression, anxiety, or personality disorders
- Lung disease, including reduced pulmonary function
- Liver or kidney impairment (dose reduction may be necessary)
- Thyroid disease, particularly hypothyroidism
- Alcoholism or chronic alcohol consumption
- Obesity (extended postoperative monitoring is recommended)
- Raised intracranial pressure or brain/skull injury
- Reduced blood volume (hypovolemia), which increases the risk of hypotension and bradycardia
Like all potent opioids, sufentanil can cause dose-dependent respiratory depression that may persist into the postoperative recovery period or recur during awakening. Sufentanil can also cause sleep-related breathing disorders including sleep apnea and sleep-related hypoxemia. Careful monitoring of respiratory function is mandatory throughout the perioperative period. If you experience breathing pauses during sleep, nighttime awakenings due to breathlessness, or excessive daytime drowsiness after receiving this medication, inform your healthcare team immediately.
Repeated use of opioid analgesics, including sufentanil, can lead to reduced effectiveness (tolerance), physical dependence, and the potential for opioid use disorder. While the risk is lower with controlled hospital administration compared to outpatient opioid use, it is important to be aware of these risks. If you feel you are developing dependence on any opioid medication, speak with your physician.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, suspect you may be pregnant, or are planning to become pregnant, consult your physician before receiving Sufentanil Hameln. The following important considerations apply:
Pregnancy: Sufentanil Hameln must not be given intravenously during labor because it readily crosses the placenta and may depress the newborn’s respiratory function. However, epidural administration of sufentanil is an accepted and widely used technique for labor analgesia, as the lower systemic absorption associated with this route results in less transfer to the fetus.
Breastfeeding: Sufentanil is excreted in breast milk. A decision must be made whether to discontinue breastfeeding or to withhold sufentanil treatment, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. Breastfeeding may be safely resumed 24 hours after the last dose of sufentanil.
Neonates and Infants
Newborns are particularly sensitive to the respiratory depressant effects of opioids, including sufentanil. Only limited data are available on the use of sufentanil in neonates via the intravenous route. Due to the risk of overdose or underdose, intravenous use during the neonatal period is not recommended. Epidural sufentanil is not recommended in children younger than one year of age. The attending physician will carefully weigh the benefits against the risks before administering Sufentanil Hameln to any neonate or infant.
Driving and Operating Machinery
After receiving Sufentanil Hameln, you must not drive or operate machinery for at least 24 hours. The sedative and psychomotor effects of sufentanil can significantly impair your ability to perform tasks requiring alertness and coordination. Discuss with your physician when it is safe to resume these activities after your procedure.
How Does Sufentanil Hameln Interact with Other Drugs?
Quick Answer: Sufentanil has clinically significant interactions with MAO inhibitors (contraindicated), benzodiazepines and other CNS depressants (risk of life-threatening respiratory depression), gabapentinoids (increased overdose risk), and CYP3A4 inhibitors such as ketoconazole and ritonavir (enhanced and prolonged opioid effects).
Drug interactions with sufentanil can be potentially life-threatening due to the extreme potency of this medication. Your anesthesiologist must be informed of all medications you are taking, including prescription drugs, over-the-counter medications, herbal supplements, and recreational substances. The following interactions are of particular clinical significance:
Major Interactions — Contraindicated or Avoid
| Drug / Drug Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| MAO Inhibitors (e.g., phenelzine, tranylcypromine) | Risk of serotonin syndrome, severe hypertension, or fatal cardiovascular collapse | Must be discontinued at least 2 weeks before surgery |
| Benzodiazepines (e.g., midazolam, diazepam, lorazepam) | Increased risk of profound sedation, respiratory depression, coma, and death | Use only when no alternatives; limit dose and duration |
| Partial opioid agonists/antagonists (nalbuphine, buprenorphine, pentazocin) | May precipitate withdrawal; can reduce analgesic efficacy | Contraindicated; discontinue before sufentanil use |
| SSRIs / SNRIs (e.g., fluoxetine, venlafaxine) | Increased risk of serotonin syndrome (agitation, tremor, hyperthermia) | Not recommended; weigh benefit vs. risk if use is essential |
| Gabapentin / Pregabalin | Increased risk of opioid overdose, respiratory depression, and death | Use with caution; monitor closely for respiratory depression |
Moderate Interactions — Use with Caution
| Drug / Drug Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Barbiturates / Sedatives / Hypnotics | Enhanced CNS depression; increased sedation and respiratory depression | Reduce doses of both agents; monitor respiratory function |
| Neuromuscular blocking agents (e.g., vecuronium, succinylcholine) | Sufentanil may enhance and prolong neuromuscular blockade | Adjust dosing; monitor with nerve stimulator |
| General anesthetics (e.g., thiopental, etomidate, nitrous oxide) | Synergistic CNS and cardiovascular depression | Dose adjustments required; standard balanced anesthesia protocols |
| Neuroleptics / Antipsychotics | Increased sedation; potential hypotension | Monitor blood pressure and sedation level |
| CYP3A4 inhibitors (erythromycin, ketoconazole, itraconazole, ritonavir) | Increased plasma concentration of sufentanil; prolonged and enhanced opioid effects | Reduce sufentanil dose; extend monitoring period |
Sufentanil is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration of potent CYP3A4 inhibitors — such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (erythromycin), and HIV protease inhibitors (ritonavir) — can significantly increase sufentanil plasma concentrations, leading to enhanced and prolonged opioid effects including respiratory depression. Your anesthesiologist will take this into account when calculating the appropriate dose.
What Is the Correct Dosage of Sufentanil Hameln?
Quick Answer: Dosage is individualized by the anesthesiologist based on the patient’s age, weight, medical condition, type and duration of surgery, and concurrent medications. Sufentanil is never self-administered and is always given by or under the supervision of an experienced anesthesiologist in a fully equipped medical facility.
The dosage of Sufentanil Hameln is determined exclusively by the attending anesthesiologist and is tailored to each individual patient. Because of the extreme potency of this drug, precise dosing is critical to achieve the desired level of analgesia and anesthesia while minimizing the risk of adverse effects, particularly respiratory depression and cardiovascular instability. The following general dosing guidance applies:
Adults — Intravenous Use
Analgesic Supplement to General Anesthesia
When used as an analgesic component of balanced anesthesia, sufentanil is given as an initial intravenous bolus followed by supplemental doses as needed. The initial dose and subsequent doses are titrated based on the patient’s response, the surgical stimulation level, and concurrent anesthetic agents. Total doses vary significantly depending on the duration and complexity of the procedure.
Primary Anesthetic Agent for Major Surgery
For use as the primary anesthetic in major surgical procedures requiring mechanical ventilation — such as cardiovascular surgery — higher doses of sufentanil are employed. These high-dose techniques provide exceptional hemodynamic stability, which is particularly valuable in patients with compromised cardiovascular function. Supplemental doses of a volatile anesthetic or benzodiazepine may be used adjunctively.
Adults — Epidural Use
Postoperative Pain and Cesarean Section
For epidural analgesia, sufentanil is typically administered as a bolus injection into the epidural space or as a continuous epidural infusion, often combined with a local anesthetic such as bupivacaine. The epidural dose is substantially lower than the intravenous dose due to the proximity to opioid receptors in the spinal cord dorsal horn. The physician will adjust the dose based on the patient’s pain level and response.
Labor Analgesia
During labor, epidural sufentanil provides effective pain relief that can be maintained with repeated bolus doses or continuous infusion. When combined with a dilute local anesthetic solution, epidural sufentanil allows the laboring mother to remain alert and mobile while experiencing significant pain reduction. The dose is carefully adjusted to balance analgesia with safety for both mother and baby.
Children
Intravenous Use (Children > 1 month)
Intravenous sufentanil is injected slowly by the anesthesiologist. The dose is calculated based on body weight and is adjusted according to the type and duration of the surgical procedure and the concurrent use of other anesthetic agents. Continuous monitoring of respiratory and cardiovascular function is mandatory throughout the procedure and recovery period.
Epidural Use (Children ≥ 1 year)
Epidural sufentanil is administered slowly into the epidural space by an anesthesiologist experienced in pediatric regional anesthesia techniques. The dose depends on the concurrent use of other anesthetics and the required duration of pain relief. Children must be monitored for signs of respiratory depression for at least 2 hours after epidural administration of Sufentanil Hameln.
Special Populations Requiring Dose Adjustment
- Elderly patients: Older adults may be more sensitive to the effects of sufentanil due to changes in body composition, organ function, and drug metabolism. Lower initial doses and careful titration are typically required.
- Hepatic impairment: Sufentanil is primarily metabolized in the liver. Patients with liver disease require dose reduction and extended monitoring, as drug clearance may be significantly delayed.
- Renal impairment: Although renal elimination plays a minor role in sufentanil clearance, patients with kidney disease may require dose adjustment and extended monitoring.
- Hypothyroidism: Patients with underactive thyroid require careful dose adjustment, as they may experience enhanced and prolonged opioid effects.
- Obesity: Dose calculations in obese patients require special consideration. Extended postoperative monitoring of vital signs is recommended.
- Debilitated patients: Lower doses are required for patients who are weak, malnourished, or in poor general condition.
Overdose
Since Sufentanil Hameln is administered by a physician under carefully controlled hospital conditions, overdose is highly unlikely. In the extremely rare event of accidental overdose, symptoms may include severe respiratory depression, loss of consciousness, extreme drowsiness, very slow heart rate, and dangerously low blood pressure. The healthcare team has immediate access to the opioid antagonist naloxone, which rapidly reverses the effects of sufentanil, as well as equipment for mechanical ventilation and advanced cardiovascular life support.
If you or someone else experiences breathing difficulties after receiving any opioid medication, inform the medical team immediately. In the event of overdose outside a healthcare facility, call your local emergency number immediately. Do not attempt to treat opioid overdose at home without professional assistance.
What Are the Side Effects of Sufentanil Hameln?
Quick Answer: The most common side effects are sedation and itching (pruritus), affecting more than 1 in 10 patients. Common effects include nausea, vomiting, blood pressure changes, and rapid heart rate. Serious but rare complications include respiratory arrest, cardiac arrest, and severe allergic reactions.
Like all opioid medications, Sufentanil Hameln can cause side effects, although not everyone experiences them. The type and severity of side effects depend on the dose administered, the route of administration (intravenous or epidural), the duration of use, and individual patient factors. Side effects are managed by the anesthesiologist and nursing staff during and after your procedure. If you experience any unusual symptoms, inform your healthcare team immediately.
The following side effects are organized by frequency according to international pharmacovigilance conventions:
Very Common
May affect more than 1 in 10 patients
- Sedation (drowsiness, sleepiness)
- Pruritus (itching), particularly with epidural administration
Common
May affect up to 1 in 10 patients
- Nausea and vomiting
- Hypertension (high blood pressure) or hypotension (low blood pressure)
- Tachycardia (rapid heart rate)
- Pallor (paleness)
- Cyanosis in neonates (bluish discoloration due to low oxygen)
- Skin discoloration
- Muscle twitching or involuntary movements
- Urinary retention or urinary incontinence
- Fever
- Headache and dizziness
- Involuntary muscle movements in neonates
Uncommon
May affect up to 1 in 100 patients
- Irregular heartbeat (cardiac arrhythmia)
- Decreased muscle tone in neonates
- Back pain
- Hypersensitivity reactions
- Runny nose (rhinitis)
- Apathy (emotional indifference) or nervousness
- Impaired muscle coordination (ataxia)
- Sustained involuntary muscle contractions (dystonia)
- Hyperactive reflexes (hyperreflexia)
- Increased muscle tone (hypertonia)
- Reduced motility in neonates
- Drowsiness or visual disturbances
- Allergic skin reaction, rash, abnormal sweating, or dry skin
- Intraoperative muscle movements (myoclonus)
- Chills or body temperature changes
- Respiratory difficulty or bronchospasm
- Bradycardia (slow heart rate)
- Cough, hiccups, or voice changes
- Cyanosis (bluish skin coloration due to low oxygen)
- ECG abnormalities
- Chest wall rigidity potentially impairing breathing
- Injection site reaction or pain
- Skin rash in neonates
Not Known Frequency
Cannot be estimated from available data
- Miosis (constricted pupils)
- Respiratory depression or respiratory arrest
- Anaphylaxis (severe allergic reaction with rash, breathing difficulty, and shock)
- Euphoria (overwhelming sense of well-being)
- Involuntary movements (dyskinesia)
- Cardiac arrest
- Laryngospasm (throat muscle spasm)
- Vertigo (difficulty standing or a spinning sensation)
- Coma
- Seizures (convulsions)
- Pulmonary edema (fluid in the lungs)
- Flushing (skin redness)
- Muscle spasms or rigidity
Side Effects in Children
The frequency, type, and severity of side effects in children and adolescents are expected to be the same as those observed in adult patients. However, neonates and infants may be more susceptible to respiratory depression and may exhibit specific effects such as cyanosis, involuntary muscle movements, and decreased muscle tone. Continuous monitoring by experienced pediatric anesthesiologists is essential when sufentanil is used in the pediatric population.
If you experience any side effects after receiving Sufentanil Hameln — including those not listed above — report them to your healthcare provider. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide valuable information about the safety of medicines.
How Should You Store Sufentanil Hameln?
Quick Answer: Sufentanil Hameln must be stored below 25°C, protected from light in the original packaging, and kept out of the reach of children. It should be used immediately after opening. The physician or pharmacist is responsible for proper storage and disposal.
Sufentanil Hameln is a controlled substance that requires strict storage and handling procedures. As a hospital-only medication, patients are not typically responsible for its storage, but understanding these requirements contributes to medication safety awareness.
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Light protection: Keep the ampoules in the outer carton to protect from light, as sufentanil is light-sensitive.
- Use after opening: The product should be used immediately after opening the ampoule. Any unused solution should be discarded.
- Diluted solution stability: Chemical and physical in-use stability of diluted solutions has been demonstrated for up to 72 hours at 20–25°C. From a microbiological standpoint, the product should be used immediately. If not used immediately, the storage time after dilution should normally not exceed 24 hours at 2–8°C unless dilution has been performed under controlled and validated aseptic conditions.
- Expiry date: Do not use after the expiry date stated on the label and carton (EXP). The expiry date refers to the last day of the stated month.
- Visual inspection: Do not use Sufentanil Hameln if the solution is not clear and free from particles, or if the container is damaged.
- Child safety: Keep this medicine out of the sight and reach of children at all times.
The physician, pharmacist, or other authorized healthcare professional is responsible for the correct storage, use, and disposal of Sufentanil Hameln in accordance with applicable controlled substance regulations.
What Does Sufentanil Hameln Contain?
Quick Answer: The active substance is sufentanil (as sufentanil citrate). Other ingredients are sodium chloride, citric acid monohydrate, and water for injections. It is a clear, colorless solution supplied in glass ampoules.
Active Substance
The active pharmaceutical ingredient is sufentanil, present in the formulation as sufentanil citrate. Two concentration strengths are available:
| Strength | Ampoule Volume | Sufentanil Content | Sufentanil Citrate Content |
|---|---|---|---|
| 5 mcg/ml | 2 ml | 10 mcg | 15 mcg |
| 5 mcg/ml | 10 ml | 50 mcg | 75 mcg |
| 50 mcg/ml | 1 ml | 50 mcg | 75 mcg |
| 50 mcg/ml | 5 ml | 250 mcg | 375 mcg |
| 50 mcg/ml | 20 ml | 1,000 mcg | 1,500 mcg |
Inactive Ingredients (Excipients)
- Sodium chloride: Used to adjust the osmolality (salt balance) of the solution to make it compatible with body fluids.
- Citric acid monohydrate: Used as a pH adjuster and buffering agent to maintain solution stability.
- Water for injections: The solvent base, prepared to pharmaceutical purity standards.
Sodium content: This medicine contains 3.54 mg sodium (the main component of table salt) per milliliter of solution. This is equivalent to approximately 0.2% of the recommended maximum daily sodium intake for adults.
Physical Appearance and Packaging
Sufentanil Hameln is a clear, colorless solution supplied in colorless glass ampoules. The 5 mcg/ml strength is available in packs of 5 or 10 ampoules containing 2 ml or 10 ml of solution each. The 50 mcg/ml strength is available in packs of 5 or 10 ampoules containing 1 ml, 5 ml, or 20 ml of solution each. Not all pack sizes may be marketed in every country.
Compatibility Information for Healthcare Professionals
Sufentanil citrate solution may be mixed with Ringer’s lactate solution, 0.9% sodium chloride solution, or 5% glucose solution for infusion. For epidural use, it may be mixed with 0.9% sodium chloride and/or bupivacaine solution. Note that sufentanil citrate is physically incompatible with diazepam, lorazepam, phenobarbital sodium, phenytoin sodium, and thiopental sodium — these must not be mixed in the same syringe or infusion line.
Frequently Asked Questions About Sufentanil Hameln
Sufentanil Hameln is a potent opioid analgesic used exclusively in hospital settings. It is administered intravenously for analgesia during induction and maintenance of general anesthesia in major surgeries, and epidurally for postoperative pain relief, labor analgesia, and pain management after cesarean section. It is only given by or under the supervision of a qualified anesthesiologist with immediate access to resuscitation equipment and mechanical ventilation.
Sufentanil is one of the most potent opioids available in clinical practice. It is approximately 5 to 10 times more potent than fentanyl and 500 to 1,000 times more potent than morphine on a weight-for-weight basis. This extreme potency means that very small doses (measured in micrograms) are sufficient to produce the desired analgesic and anesthetic effects, which is advantageous for cardiovascular stability during major surgical procedures.
The most serious risk is respiratory depression, which can be life-threatening. Sufentanil can slow or stop breathing, and this effect may persist into the recovery period or recur during awakening. Other serious risks include cardiac arrest (extremely rare), severe allergic reactions (anaphylaxis), chest wall rigidity impairing ventilation, and dangerous interactions with other CNS depressants. These risks are managed through continuous monitoring by trained anesthesiologists in fully equipped medical facilities.
Intravenous sufentanil must not be given during labor or before the umbilical cord has been clamped during cesarean section, as it crosses the placenta and may affect the baby’s breathing. However, epidural administration of sufentanil is a widely accepted and commonly used technique for labor analgesia, providing effective pain relief during childbirth with reduced transfer to the fetus compared to intravenous administration.
Like all opioids, sufentanil has the potential for tolerance, physical dependence, and misuse. However, the risk of addiction from controlled hospital administration during surgery or the immediate postoperative period is substantially lower than from prolonged outpatient opioid therapy. Sufentanil Hameln is administered only by medical professionals in monitored settings, and doses are carefully controlled. If you have a history of substance use disorder, inform your anesthesiologist so that appropriate precautions can be taken.
Sufentanil is excreted in breast milk. Breastfeeding can be safely resumed 24 hours after the last dose of sufentanil. During this 24-hour waiting period, you may need to express and discard breast milk to maintain your milk supply. Discuss the timing of breastfeeding resumption with your healthcare team, particularly if you received additional opioid medications during or after your procedure.
References and Sources
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Sufentanil — Summary of Product Characteristics (SmPC). European public assessment database. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Sufentanil — Drug Monograph. National Institute for Health and Care Excellence (NICE). Updated 2025.
- Scholz J, Steinfath M, Schulz M. “Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: an update.” Clinical Pharmacokinetics. 1996;31(4):275–292. doi:10.2165/00003088-199631040-00004
- Bailey PL, Streisand JB, East KA, et al. “Differences in magnitude and duration of opioid-induced respiratory depression and analgesia with fentanyl and sufentanil.” Anesthesia & Analgesia. 1990;70(1):8–15.
- Rosow CE. “Sufentanil citrate: a new opioid analgesic for use in anesthesia.” Pharmacotherapy. 1984;4(1):11–19.
- Grass JA. “Sufentanil: clinical use as postoperative analgesic — epidural/intrathecal route.” Journal of Pain and Symptom Management. 1992;7(5):271–286.
- American Society of Anesthesiologists (ASA). “Practice Guidelines for Perioperative Management of Patients with Opioid Use Disorder.” Anesthesiology. 2023;138(2):218–245.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(3):1–95.
- U.S. Food and Drug Administration (FDA). Sufentanil Citrate Injection — Prescribing Information. FDA Drug Database. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist qualifications in anesthesiology, pharmacology, and pain medicine. All content follows the GRADE evidence framework and is reviewed according to international medical standards.
iMedic Medical Editorial Team — Specialists in Anesthesiology and Clinical Pharmacology
iMedic Medical Review Board — Independent expert panel reviewing all content according to WHO, EMA, and FDA guidelines
All medical claims supported by Level 1A evidence: systematic reviews and meta-analyses of randomized controlled trials
No pharmaceutical company funding, sponsorship, or advertising. Fully independent medical editorial content.